CClinicalTrials.gg
Not yet recruitingNCT07482683Updated Mar 19, 2026

Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach

An observational study in Acute Kidney Disease, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by China National Center for Cardiovascular Diseases · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
820
Ages
18 Years and older
Sex
All
01

Study summary

Renal injury after cardiac surgery is one of the common complications with high incidence rate, high risk of death and progression to chronic kidney disease (CKD). Previous evaluations of perioperative renal function mainly focused on acute kidney injury (AKI) related to cardiac surgery within seven days after surgery. The newly proposed concept of acute kidney disease (AKD) in recent years refers to acute or subacute kidney injury lasting seven to ninety days. Research has found that AKD can occur after AKI or in patients without AKI, and the two are both related and independent of each other, possibly indicating different subtypes of kidney injury. AKD is not uncommon and is a more significant predictor of mortality and end-stage kidney disease (ESKD). Therefore, AKD may be an important window for identifying and managing high-risk patients after cardiac surgery. Due to limited research on AKD after cardiac surgery, the risk factors for AKD are currently unclear, and there are no clinically practical and effective risk stratification tools available. This study aims to establish a multimodal perioperative data platform through a retrospective cohort, and use machine learning methods to construct a risk prediction model for AKD after cardiac surgery. The accuracy and stability of the model will be validated in a prospective study cohort, and an online risk prediction and clinical decision-making tool will be developed to help clinicians quickly conduct personalized risk assessments and optimize diagnosis and treatment strategies, thereby improving patient prognosis and reducing medical costs.

02

Conditions studied

  • Acute Kidney Disease
03

In context

Lead sponsor

China National Center for Cardiovascular Diseases is the lead sponsor of 256 studies on the registry; 134 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients undergoing cardiac surgery at Fuwai Hospital

Inclusion criteria

  • Age ≥ 18 years;
  • Undergoing coronary artery bypass grafting and/or heart valve surgery, with or without aortic surgery;
  • Baseline serum creatinine level \< 354 umol/L;
  • Informed consent obtained.

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery;
  • Multiple surgeries or reoperation;
  • End-stage kidney disease (ESKD), renal replacement therapy, or kidney transplantation;
  • Occurrence of AKI within 1 week before surgery or unresolved AKI;
  • Death within 1 week after surgery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
820 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients undergoing coronary artery bypass grafting and/or heart valve surgery
06

What researchers measure

Primary outcomes

  1. Number of Participants with acute kidney disease after cardiac surgery Assessed by KDIGO guideline

    Time frame: within 90 days after cardiac surgery

  2. acute kidney disease after cardiac surgery

    Time frame: within 90 days after cardiac surgery

07

Study locations

1 site
  • National Center for Cardiovascular Diseases
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482683
Lead sponsor
China National Center for Cardiovascular Diseases
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Lili Liu
Contact
lll9536@sina.com
86-010-88396533

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion